Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 367Ovarian Neoplasms 99Lung Neoplasms 98Neoplasms 84Small Cell Lung Carcinoma 71Breast Neoplasms 59Neoplasm Metastasis 49Triple Negative Breast Neoplasms 46Parkinson Disease 4, Autosomal Dominant Lewy Body 41Fallopian Tube Neoplasms 38Squamous Cell Carcinoma of Head and Neck 33Endometrial Neoplasms 30Carcinoma 30Uterine Cervical Neoplasms 28Colorectal Neoplasms 24Carcinoma, Ovarian Epithelial 23Head and Neck Neoplasms 19Carcinoma, Transitional Cell 18Urinary Bladder Neoplasms 17Advanced Solid Tumors 17Recurrence 15Melanoma 14Stomach Neoplasms 13Peritoneal Neoplasms 13Pancreatic Neoplasms 12Adenocarcinoma 11Lung Diseases 9Glioblastoma 9Carcinoma, Squamous Cell 9Thoracic Neoplasms 8

Interventions

Injections 3Fluorouracil 2Cisplatin 2toripalimab 1spartalizumab 1pembrolizumab 1SHR-1701 1Paclitaxel 1Oxaliplatin 1Irinotecan 1Gemcitabine 1Drug Therapy 1Docetaxel 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Malignant Tumors × Carboplatin × Clear all
NCT05229497 2026-03-09

A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors

Akeso

Phase 1/2 Active not recruiting
154 enrolled

Advanced Malignant Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡